Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Treating patients with semaglutide -- an anti-diabetic medication -- can halt and even reverse liver disease, according to a ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.